PMC:7600245 / 49983-50215 JSONTXT

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T216","span":{"begin":185,"end":193},"obj":"Disease"}],"attributes":[{"id":"A216","pred":"mondo_id","subj":"T216","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"Currently, a prospective, randomized, multi-center, double-blinded, and placebo-controlled study is ongoing to evaluate the safety and efficacy of vidofludimus as an adjunct therapy in COVID-19 patients (NCT04379271; n = 230) [157]."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T495","span":{"begin":11,"end":12},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"Currently, a prospective, randomized, multi-center, double-blinded, and placebo-controlled study is ongoing to evaluate the safety and efficacy of vidofludimus as an adjunct therapy in COVID-19 patients (NCT04379271; n = 230) [157]."}

{"project":"LitCovid-sentences","denotations":[{"id":"T373","span":{"begin":0,"end":232},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Currently, a prospective, randomized, multi-center, double-blinded, and placebo-controlled study is ongoing to evaluate the safety and efficacy of vidofludimus as an adjunct therapy in COVID-19 patients (NCT04379271; n = 230) [157]."}

{"project":"LitCovid-PubTator","denotations":[{"id":"1566","span":{"begin":194,"end":202},"obj":"Species"},{"id":"1569","span":{"begin":147,"end":159},"obj":"Chemical"},{"id":"1573","span":{"begin":185,"end":193},"obj":"Disease"}],"attributes":[{"id":"A1566","pred":"tao:has_database_id","subj":"1566","obj":"Tax:9606"},{"id":"A1569","pred":"tao:has_database_id","subj":"1569","obj":"MESH:C553728"},{"id":"A1573","pred":"tao:has_database_id","subj":"1573","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Currently, a prospective, randomized, multi-center, double-blinded, and placebo-controlled study is ongoing to evaluate the safety and efficacy of vidofludimus as an adjunct therapy in COVID-19 patients (NCT04379271; n = 230) [157]."}